Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Transcode Therapeutics acquires option for radiotheranostic technology » 09:07
05/19/22
05/19
09:07
05/19/22
09:07
RNAZ

Transcode Therapeutics

$2.06 /

-0.14 (-6.36%)

TransCode Therapeutics is…

TransCode Therapeutics is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer. The use of radioisotopes is a emerging approach for many drug development companies in the treatment of cancer. There are a range of carriers from antibodies to small molecules that can be used to localize, penetrate and persist in tumors. TransCode is prosecuting the continued development of its iron-oxide based nanoparticle RNA delivery platform, dubbed TTX. Just as TTX has the potential to improve on the intracellular delivery of RNA therapeutics over existing lipid-based systems, TransCode believes TTX has the potential for efficient localized penetration of radioisotopes inside tumor cells. Future demonstration of these tools could enable multimodal approaches to the diagnosis and treatment of cancer. TransCode expects to submit an exploratory investigational new drug, or eIND, application to conduct a Phase 0 First-in-Human clinical trial with radiolabeled TTX-MC138 in patients with Stage IV solid tumors in the second half of 2022.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.06 /

-0.14 (-6.36%)

Hot Stocks
Transcode Therapeutics announces planned milestones » 08:35
05/16/22
05/16
08:35
05/16/22
08:35
RNAZ

Transcode Therapeutics

$2.25 /

+0.01 (+0.45%)

TransCode's goals to…

TransCode's goals to continue to advance its portfolio include: TTX-MC138 - Submission to FDA of an eIND application for its First-in-Human clinical trial. Completion of a FIH Phase 0 clinical study intended to demonstrate quantifiable evidence of delivery of radiolabeled TTX-MC138 to metastatic lesions in advanced solid tumors; measure pharmacokinetics and biodistribution in vital organs and other tissues; potentially inform therapeutic dose levels based on microdose results; and validate delivery for the TTX pipeline more broadly, potentially opening-up additional relevant RNA targets that have been previously undruggable due to challenges with RNA delivery. Concurrent completion of IND-enabling studies to support filing an IND application for a Phase I clinical trial of TTX-MC138. Publication of preclinical results supporting the lead therapeutic candidate, TTX-MC138, in pancreatic cancer and glioblastoma multiforme. Publication of preclinical results supporting therapeutic candidate, TTX-RIGA. Continuation of preclinical studies for therapeutic candidates TTX-RIGA, TTX-siPDL1, and TTX-siLIN28B. Continuation of discussions regarding potential partnerships. File for Orphan Drug Designation for its lead therapeutic candidate in additional tumor indications.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.25 /

+0.01 (+0.45%)

Hot Stocks
Transcode Therapeutics expects cash to fund operations into Q1 of 2023 » 08:35
05/16/22
05/16
08:35
05/16/22
08:35
RNAZ

Transcode Therapeutics

$2.25 /

+0.01 (+0.45%)

TransCode expects that…

TransCode expects that its cash of $16.9 million as of March 31, 2022, together with additional funding expected from the April 2021 SBIR award, are sufficient to fund planned operations into the first quarter 2023 but not for a full 12 months from the date of its financial statements.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.25 /

+0.01 (+0.45%)

Over a month ago
Hot Stocks
Transcode Therapeutics publishes article in journal Cancers » 09:06
03/23/22
03/23
09:06
03/23/22
09:06
RNAZ

Transcode Therapeutics

$2.52 /

-0.08 (-3.08%)

TransCode Therapeutics,…

TransCode Therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. The article was published on March 21, 2022. The article describes the development, challenges, and clinical successes of short RNA-based drugs and details several examples of how these RNA drugs are designed, chemically modified, and delivered for treatment of cancer, cardiovascular disease, and rare genetic disorders. In addition, the article highlights key similarities and differences between various short non-coding RNA platforms and discusses considerations to maximize treatment efficacy of RNA-based therapeutics. TransCode's CEO, Michael Dudley, added, "We believe RNA-based drugs will play an increasingly important role in personalized treatment for cancer and other diseases. Our first-in-human clinical trial which we intend to initiate later this year with our lead therapeutic candidate, targets an RNA molecule that has been shown to be the driver of metastatic disease. Since our proprietary delivery system has been engineered to deliver RNA therapeutics inside tumor cells, it has the potential to overcome the challenges of RNA delivery to a range of genetic targets. We believe this would represent a major step forward in unlocking therapeutic access to genetic targets involved in a range of cancers."

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.52 /

-0.08 (-3.08%)

Over a quarter ago
Hot Stocks
Transcode announces expansion of global RNA oncology patent portfolio » 09:02
02/14/22
02/14
09:02
02/14/22
09:02
RNAZ

Transcode Therapeutics

$2.09 /

-0.27 (-11.44%)

TransCode Therapeutics…

TransCode Therapeutics announced that it has filed an International PCT Application entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY. The '580 application, expected to publish in June 2022, represents an extension of TransCode's use of its patented RNA therapeutic platform to include using pattern recognition receptors to target tumor cells by activating the RIG-I signaling pathway. Once inside a cell, the selected PRR-activating oligonucleotide encounters a microRNA specific to that tumor, activating a type I interferon-driven immune response, leading to programmed tumor cell death. The filing of the '580 application directly supports TransCode's goals of deploying the right therapy for individual cancer patients. If issued, the proposed patent would join a number of other granted patents TransCode owns or licenses, including US 9,629,812 and EP 2 961 386. As part of its overall patent strategy, TransCode is actively pursuing intellectual property protection for additional components of its discovery engine built around its TTX delivery platform. The TTX platform is currently comprised of a hemodynamic and metabolic tumor targeting delivery system suitable for deploying a variety of RNA therapeutic candidates including RNAi, pattern recognition receptors, messenger RNA, gene repair/replacement and radiolabeled therapeutics.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.09 /

-0.27 (-11.44%)

Conference/Events
Transcode Therapeutics management to meet virtually with ThinkEquity » 11:06
01/26/22
01/26
11:06
01/26/22
11:06
RNAZ

Transcode Therapeutics

$2.21 /

-0.07 (-3.07%)

Virtual Meeting to be…

Virtual Meeting to be held on January 26 hosted by ThinkEquity.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.21 /

-0.07 (-3.07%)

RNAZ Transcode Therapeutics
$2.21 /

-0.07 (-3.07%)

Hot Stocks
Transcode Therapeutics names Zdravka Medarova CTO » 16:02
09/30/21
09/30
16:02
09/30/21
16:02
RNAZ

Transcode Therapeutics

$2.98 /

-0.08 (-2.61%)

TransCode Therapeutics…

TransCode Therapeutics announced that Zdravka Medarova, Ph.D., has been appointed as the company's Chief Technology Officer effective October 1, 2021. Dr. Medarova is a scientific co-founder of TransCode and has served as a member of TransCode's advisory board since its founding in January 2016. "We are delighted to welcome Zdravka as a full-time member of the TransCode team," said Michael Dudley, CEO of TransCode. "We have long benefitted from her extensive expertise in developing nanotechnology and imaging tools to better understand cancer initiation and progression, as well as her support of our preclinical research through affiliations with Harvard Medical School and Massachusetts General Hospital. Zdravka's leadership will be invaluable as we pursue validation of our TTX platform as a viable means to bring the promise of RNA therapeutics to the treatment of cancer."

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.98 /

-0.08 (-2.61%)

RNAZ Transcode Therapeutics
$2.98 /

-0.08 (-2.61%)

Hot Stocks
Transcode announces data supporting therapeutic potential of TTX-MC138 » 07:47
09/23/21
09/23
07:47
09/23/21
07:47
RNAZ

Transcode Therapeutics

$2.64 /

+0.17 (+6.88%)

TransCode Therapeutics…

TransCode Therapeutics announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. The article, entitled "Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer," resulted from research conducted at the Athinoula A. Martinos Center for Biomedical Imaging in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School. ..The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions. These results suggest that TransCode's TTX platform delivers its therapeutic candidate as intended and the company believes supports clinical evaluation of TTX-MC138. In addition, the investigation describes the development of a microdosing PET-MRI approach that could potentially be used for measurement of TTX-MC138 biodistribution in cancer patients and its delivery to clinical metastases. The capacity to carry out microdosing PET studies in patients under an exploratory investigational new drug application protocol would represent an important step on the path to clinical translation because it could facilitate and expedite approval from the U.S. Food and Drug Administration for initial human studies. TransCode expects to file an exploratory investigational new drug, eIND, application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer. Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.64 /

+0.17 (+6.88%)

RNAZ Transcode Therapeutics
$2.64 /

+0.17 (+6.88%)

Hot Stocks
Transcode announces data supporting therapeutic potential of TTX-MC138 » 07:47
09/23/21
09/23
07:47
09/23/21
07:47
RNAZ

Transcode Therapeutics

$2.64 /

+0.17 (+6.88%)

TransCode Therapeutics…

TransCode Therapeutics announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. The article, entitled "Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer," resulted from research conducted at the Athinoula A. Martinos Center for Biomedical Imaging in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School. ..The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions. These results suggest that TransCode's TTX platform delivers its therapeutic candidate as intended and the company believes supports clinical evaluation of TTX-MC138. In addition, the investigation describes the development of a microdosing PET-MRI approach that could potentially be used for measurement of TTX-MC138 biodistribution in cancer patients and its delivery to clinical metastases. The capacity to carry out microdosing PET studies in patients under an exploratory investigational new drug application protocol would represent an important step on the path to clinical translation because it could facilitate and expedite approval from the U.S. Food and Drug Administration for initial human studies. TransCode expects to file an exploratory investigational new drug, eIND, application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer. Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.

ShowHide Related Items >><<
RNAZ Transcode Therapeutics
$2.64 /

+0.17 (+6.88%)

On The Fly
Opening Day: Robinhood shares fall after IPO » 08:53
07/31/21
07/31
08:53
07/31/21
08:53
MXCT

MaxCyte

$16.89 /

-0.11 (-0.65%)

, RXST

RxSight

$16.42 /

-1.33 (-7.49%)

, TNYA

Tenaya Therapeutics

$15.75 /

-3.94 (-20.01%)

, RANI

Rani Therapeutics

$10.95 /

-0.37 (-3.27%)

, OMGA

Omega Therapeutics

$16.05 /

-4.43 (-21.63%)

, IMRX

Immuneering

$17.72 /

-1.94 (-9.87%)

, INAB

In8bio

$10.01 /

-0.13 (-1.28%)

, DOLE

Dole

$14.55 /

-0.65 (-4.28%)

, HOOD

Robinhood

$35.57 /

+0.75 (+2.15%)

, NUVL

Nuvalent

$18.42 /

-0.39 (-2.07%)

, ICVX

Icosavax

$25.00 /

-8.68 (-25.77%)

, RSKD

Riskified

$27.18 /

+0.99 (+3.78%)

, COOK

Traeger

$22.21 /

+0.2 (+0.91%)

, RLYB

Rallybio

$17.42 /

+3.02 (+20.97%)

, DUOL

Duolingo

$140.08 /

+3.13 (+2.29%)

, MLNK

MeridianLink

$23.90 /

-0.63 (-2.57%)

, PWSC

PowerSchool

$18.49 /

+0.02 (+0.11%)

, CADL

Candel Therapeutics

$7.63 /

+0.06 (+0.79%)

, SNTG

Sentage

$5.36 /

+0.55 (+11.43%)

, RNAZ

Transcode Therapeutics

$2.96 /

+0.035 (+1.20%)

, AGRI

AgriFORCE Growing Systems

$3.42 /

+0.32 (+10.32%)

, MITQ

Moving iMage

$3.89 /

-0.1 (-2.51%)

, IINN

Inspira Technologies

$3.88 /

-0.05 (-1.27%)

, UNCY

Unicycive Therapeutics

$2.76 /

-0.05 (-1.78%)

, SPRK

Spark Education

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, MS

Morgan Stanley

$95.97 /

-0.295 (-0.31%)

, GS

Goldman Sachs

$375.04 /

-2.43 (-0.64%)

, BCS

Barclays

$9.78 /

-0.18 (-1.81%)

, BAC

Bank of America

$38.35 /

-0.335 (-0.87%)

, BLK

BlackRock

$867.23 /

-1.6 (-0.18%)

, SPG

Simon Property

$126.52 /

+0.63 (+0.50%)

Shares of Robinhood…

ShowHide Related Items >><<
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

RLYB Rallybio
$17.42 /

+3.02 (+20.97%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

MITQ Moving iMage
$3.89 /

-0.1 (-2.51%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

AGRI AgriFORCE Growing Systems
$3.42 /

+0.32 (+10.32%)

MXCT MaxCyte
$16.89 /

-0.11 (-0.65%)

RXST RxSight
$16.42 /

-1.33 (-7.49%)

TNYA Tenaya Therapeutics
$15.75 /

-3.94 (-20.01%)

RANI Rani Therapeutics
$10.95 /

-0.37 (-3.27%)

OMGA Omega Therapeutics
$16.05 /

-4.43 (-21.63%)

IMRX Immuneering
$17.72 /

-1.94 (-9.87%)

INAB In8bio
$10.01 /

-0.13 (-1.28%)

DOLE Dole
$14.55 /

-0.65 (-4.28%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

07/29/21
Fly Intel: Top five analyst initiations
07/29/21 Atlantic Equities
Robinhood initiated with an Overweight at Atlantic Equities
NUVL Nuvalent
$18.42 /

-0.39 (-2.07%)

ICVX Icosavax
$25.00 /

-8.68 (-25.77%)

RSKD Riskified
$27.18 /

+0.99 (+3.78%)

COOK Traeger
$22.21 /

+0.2 (+0.91%)

RLYB Rallybio
$17.42 /

+3.02 (+20.97%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

MLNK MeridianLink
$23.90 /

-0.63 (-2.57%)

PWSC PowerSchool
$18.49 /

+0.02 (+0.11%)

CADL Candel Therapeutics
$7.63 /

+0.06 (+0.79%)

SNTG Sentage
$5.36 /

+0.55 (+11.43%)

RNAZ Transcode Therapeutics
$2.96 /

+0.035 (+1.20%)

AGRI AgriFORCE Growing Systems
$3.42 /

+0.32 (+10.32%)

MITQ Moving iMage
$3.89 /

-0.1 (-2.51%)

IINN Inspira Technologies
$3.88 /

-0.05 (-1.27%)

UNCY Unicycive Therapeutics
$2.76 /

-0.05 (-1.78%)

SPRK Spark Education
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
07/16/21 BMO Capital
Morgan Stanley price target raised to $103 from $97 at BMO Capital
07/16/21 Piper Sandler
Morgan Stanley price target raised to $100 from $93 at Piper Sandler
GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$9.78 /

-0.18 (-1.81%)

07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
07/29/21 Societe Generale
Barclays price target raised to 180 GBp from 170 GBp at Societe Generale
BAC Bank of America
$38.35 /

-0.335 (-0.87%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
BLK BlackRock
$867.23 /

-1.6 (-0.18%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

07/19/21 Stifel
Simon Property upgraded to Buy from Hold at Stifel
06/28/21 Scotiabank
Simon Property price target raised to $138 from $117 at Scotiabank
06/22/21 Truist
Simon Property price target raised to $130 from $102 at Truist
06/21/21 Stifel
Simon Property price target raised to $125 from $120 at Stifel
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 29
    Jul
  • 29
    Jul
  • 28
    Jul
  • 28
    Jul
  • 30
    Jul
  • 28
    Jul
  • 29
    Jul
  • 29
    Jul
  • 27
    Jul
  • 14
    Jul
  • 16
    Jul
  • 08
    Jul
  • 08
    Jul
  • 08
    Jul
  • 19
    Nov
  • 13
    Nov
MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

DOLE Dole
$14.55 /

-0.65 (-4.28%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPRK Spark Education
/

+

SPG Simon Property
$126.52 /

+0.63 (+0.50%)

RXST RxSight
$16.42 /

-1.33 (-7.49%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$126.52 /

+0.63 (+0.50%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.